Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. - Wikidata - wikimedia - TriplyDB

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.

http://www.wikidata.org/entity/Q37052769

about

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems Olanzapine versus other atypical antipsychotics for schizophrenia The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics.

P2860

Q24235450-18855F56-654F-476F-9876-20ECCBECEBC3 Q24236545-7D96EA83-50D8-412E-B5AE-AD957BF97C80 Q36240230-CEF828BB-8393-4FD8-8FF9-8106B4678E41 Q37676725-C5398F37-8DF2-430E-A1E8-E233141C0398 Q40427460-B69F0C40-5214-4DD2-A8C4-62922DEF45C3 Q42905755-1DE0040D-5BAA-41AD-A1E8-024CA220FE9B Q51399602-EA6CF325-A17A-455B-A8F5-B2601C1912BD

P2860

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.

http://www.wikidata.org/entity/Q37052769

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Double-blind, randomized trial ...... a or schizoaffective disorder.

@en

Double-blind, randomized trial ...... a or schizoaffective disorder.

@nl

type

label

Double-blind, randomized trial ...... a or schizoaffective disorder.

@en

Double-blind, randomized trial ...... a or schizoaffective disorder.

@nl

prefLabel

Double-blind, randomized trial ...... a or schizoaffective disorder.

@en

Double-blind, randomized trial ...... a or schizoaffective disorder.

@nl

P1433

Q37052769-26AF8701-E8B1-427F-837F-4C21B791A550

P1476

Q37052769-3DA2AFA4-F0B0-41CB-ADC0-D252EBAA9C93

P2093

Q37052769-2AED0518-EDED-4168-B6F0-7C1E8193B61F

Q37052769-4A5BAC8D-B765-4CF7-A265-55157147B81F

Q37052769-73CCCD8B-C268-4BF8-A52B-B0697C6A100E

Q37052769-88536475-5025-4668-8372-F4AA54321333

Q37052769-AF5F74E5-722E-434F-BC9B-2357B907B240

Q37052769-AFF0088C-150A-4E93-9D40-F196CB82C159

Q37052769-B317A9B4-60AF-4FB6-A8A0-E5DEA3086420

Q37052769-E999DB55-3F9F-41D5-B7F8-7A20ECAD6DE9

P2860

Q37052769-18CF46AF-BFBB-4EBF-BF80-973223F1B1B7

Q37052769-270A9C3E-E3E5-446D-8220-E09F29A1357E

Q37052769-303B375B-4DE8-456E-83B7-081F98B9B9F4

Q37052769-33430F50-FE8E-4B74-94E1-2AD3F3857AA0

Q37052769-3AE5B650-B463-45DC-BEC6-F20946142845

Q37052769-4C3FAD8E-6312-4394-9B96-1429F95D902E

Q37052769-4C9DBDBB-819F-4A61-96E7-3D1884FE0CEF

Q37052769-652E356E-336D-4342-AC70-B9E8874FCCA4

Q37052769-A58BC5C8-F8CB-45FC-B573-9807159E7F9B

Q37052769-AD1CEB25-7DE0-4DA0-81CF-CF9A2F236D81

P304

Q37052769-EF92EB66-7F6B-4BDC-B195-89E30CB05F9D

P31

Q37052769-AFF3E1E4-5C00-4ADF-BA7B-D61F58A52CF3

P356

Q37052769-47A44E11-316C-42EF-9953-D993CBD6D1B7

P433

Q37052769-E43EFD44-615E-4970-9F73-6A630D04E98A

P478

Q37052769-A309DB8E-644D-4766-8249-27F96ADAF193

P577

Q37052769-CEF0E353-776D-4EFA-BDAB-0A16EB0B7A73

P698

Q37052769-ED90E068-0AD8-413B-8FFF-187B39151A10

P921

Q37052769-5A90D876-31EE-466C-A069-F4EDBC7EA2BC

Q37052769-8DF3221E-9881-4067-9546-661D267D14FF

P932

Q37052769-30A6BAC1-D901-4C5D-AFD3-F6809E03EC10

P356

P1433

Therapeutics and Clinical Risk Management

P1476

Double-blind, randomized trial ...... a or schizoaffective disorder.

@en

P2093

Alexandra N Heinloth

http://www.w3.org/2001/XMLSchema#string

Ilya Lipkovich

http://www.w3.org/2001/XMLSchema#string

Lin Liu

http://www.w3.org/2001/XMLSchema#string

Sara E Edwards

http://www.w3.org/2001/XMLSchema#string

Sara Kollack-Walker

http://www.w3.org/2001/XMLSchema#string

Thomas A Hardy

http://www.w3.org/2001/XMLSchema#string

Vicki Poole Hoffmann

http://www.w3.org/2001/XMLSchema#string

Walter Deberdt

http://www.w3.org/2001/XMLSchema#string

P2860

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.

The positive and negative syndrome scale (PANSS) for schizophrenia

Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

Compliance with medication regimens for mental and physical disorders.

Weight decline in patients switching from olanzapine to quetiapine.

Amantadine for weight gain associated with olanzapine treatment.

P304

713-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S3153

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19209252

http://www.w3.org/2001/XMLSchema#string

P921

P932

2621385

http://www.w3.org/2001/XMLSchema#string